BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 32719744)

  • 1. Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer in Men With a High Baseline International Prostate Symptom Score (IPSS ≥ 15).
    Aghdam N; Pepin A; Buchberger D; Hirshberg J; Lei S; Ayoob M; Danner M; Yung T; Kumar D; Collins BT; Lynch J; Kataria S; Suy S; Collins SP
    Front Oncol; 2020; 10():1060. PubMed ID: 32719744
    [No Abstract]   [Full Text] [Related]  

  • 2. Urinary Morbidity in Men Treated With Stereotactic Body Radiation Therapy (SBRT) for Localized Prostate Cancer Following Transurethral Resection of the Prostate (TURP).
    Pepin A; Aghdam N; Shah S; Kataria S; Tsou H; Datta S; Danner M; Ayoob M; Yung T; Lei S; Gurka M; Collins BT; Krishnan P; Suy S; Hankins R; Lynch JH; Collins SP
    Front Oncol; 2020; 10():555. PubMed ID: 32432033
    [No Abstract]   [Full Text] [Related]  

  • 3. Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience.
    Chen LN; Suy S; Uhm S; Oermann EK; Ju AW; Chen V; Hanscom HN; Laing S; Kim JS; Lei S; Batipps GP; Kowalczyk K; Bandi G; Pahira J; McGeagh KG; Collins BT; Krishnan P; Dawson NA; Taylor KL; Dritschilo A; Lynch JH; Collins SP
    Radiat Oncol; 2013 Mar; 8():58. PubMed ID: 23497695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stereotactic body radiation therapy (SBRT) for prostate cancer in men with large prostates (≥50 cm(3)).
    Janowski E; Chen LN; Kim JS; Lei S; Suy S; Collins B; Lynch J; Dritschilo A; Collins S
    Radiat Oncol; 2014 Nov; 9():241. PubMed ID: 25398516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved irritative voiding symptoms 3 years after stereotactic body radiation therapy for prostate cancer.
    Rana Z; Cyr RA; Chen LN; Kim BS; Moures RA; Yung TM; Lei S; Collins BT; Suy S; Dritschilo A; Lynch JH; Collins SP
    Front Oncol; 2014; 4():290. PubMed ID: 25374844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute Urinary Morbidity Following Stereotactic Body Radiation Therapy for Prostate Cancer with Prophylactic Alpha-Adrenergic Antagonist and Urethral Dose Reduction.
    Repka MC; Guleria S; Cyr RA; Yung TM; Koneru H; Chen LN; Lei S; Collins BT; Krishnan P; Suy S; Dritschilo A; Lynch J; Collins SP
    Front Oncol; 2016; 6():122. PubMed ID: 27242962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical characteristics and management of late urinary symptom flare following stereotactic body radiation therapy for prostate cancer.
    Woo JA; Chen LN; Bhagat A; Oermann EK; Kim JS; Moures R; Yung T; Lei S; Collins BT; Kumar D; Suy S; Dritschilo A; Lynch JH; Collins SP
    Front Oncol; 2014; 4():122. PubMed ID: 24904833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Age on Patient-Reported Outcomes Following Stereotactic Body Radiation Therapy for Prostate Cancer.
    Pepin A; Pernia M; Danner MT; Ayoob M; Yung TM; Lei S; Collins BT; Simeng S; Aghdam N; Collins SP
    Cureus; 2021 Mar; 13(3):e13780. PubMed ID: 33842156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stereotactic Body Radiation Therapy for Prostate Cancer: What is the Appropriate Patient-Reported Outcome for Clinical Trial Design?
    Woo JA; Chen LN; Wang H; Cyr RA; Bhattasali O; Kim JS; Moures R; Yung TM; Lei S; Collins BT; Suy S; Dritschilo A; Lynch JH; Collins SP
    Front Oncol; 2015; 5():77. PubMed ID: 25874188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urinary Outcomes for Men With High Baseline International Prostate Symptom Scores Treated With Prostate SBRT.
    Gorovets D; Hopkins M; Goldman DA; Abitbol RL; Zhang Z; Kollmeier M; McBride S; Zelefsky MJ
    Adv Radiat Oncol; 2021; 6(1):100582. PubMed ID: 33665486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient-reported outcomes following stereotactic body radiation therapy for clinically localized prostate cancer.
    Bhattasali O; Chen LN; Woo J; Park JW; Kim JS; Moures R; Yung T; Lei S; Collins BT; Kowalczyk K; Suy S; Dritschilo A; Lynch JH; Collins SP
    Radiat Oncol; 2014 Feb; 9():52. PubMed ID: 24512837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Obstructive voiding symptoms following stereotactic body radiation therapy for prostate cancer.
    Arscott WT; Chen LN; Wilson N; Bhagat A; Kim JS; Moures RA; Yung TM; Lei S; Collins BT; Kowalczyk K; Suy S; Dritschilo A; Lynch JH; Collins SP
    Radiat Oncol; 2014 Jul; 9():163. PubMed ID: 25056726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potency preservation following stereotactic body radiation therapy for prostate cancer.
    Obayomi-Davies O; Chen LN; Bhagat A; Wright HC; Uhm S; Kim JS; Yung TM; Lei S; Batipps GP; Pahira J; McGeagh KG; Collins BT; Kowalczyk K; Bandi G; Kumar D; Suy S; Dritschilo A; Lynch JH; Collins SP
    Radiat Oncol; 2013 Nov; 8():256. PubMed ID: 24180317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bleeding Risk Following Stereotactic Body Radiation Therapy for Localized Prostate Cancer in Men on Baseline Anticoagulant or Antiplatelet Therapy.
    Pepin A; Shah S; Pernia M; Lei S; Ayoob M; Danner M; Yung T; Collins BT; Suy S; Aghdam N; Collins SP
    Front Oncol; 2021; 11():722852. PubMed ID: 34604059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sexual, irritative, and voiding outcomes, following stereotactic body radiation therapy for prostate cancer.
    Rana Z; Hong RL; Abugideiri M; McRae D; Cernica G; Mordkin R; Joel AB; Bernstein G; Nasr NM
    Radiat Oncol; 2015 Aug; 10():182. PubMed ID: 26310244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pilot study of intensity modulated radiation therapy with hypofractionated stereotactic body radiation therapy (SBRT) boost in the treatment of intermediate- to high-risk prostate cancer.
    Oermann EK; Slack RS; Hanscom HN; Lei S; Suy S; Park HU; Kim JS; Sherer BA; Collins BT; Satinsky AN; Harter KW; Batipps GP; Constantinople NL; Dejter SW; Maxted WC; Regan JB; Pahira JJ; McGeagh KG; Jha RC; Dawson NA; Dritschilo A; Lynch JH; Collins SP
    Technol Cancer Res Treat; 2010 Oct; 9(5):453-62. PubMed ID: 20815416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proctitis 1 Week after Stereotactic Body Radiation Therapy for Prostate Cancer: Implications for Clinical Trial Design.
    Paydar I; Cyr RA; Yung TM; Lei S; Collins BT; Chen LN; Suy S; Dritschilo A; Lynch JH; Collins SP
    Front Oncol; 2016; 6():167. PubMed ID: 27489794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proctitis following stereotactic body radiation therapy for prostate cancer.
    Joh DY; Chen LN; Porter G; Bhagat A; Sood S; Kim JS; Moures R; Yung T; Lei S; Collins BT; Ju AW; Suy S; Carroll J; Lynch JH; Dritschilo A; Collins SP
    Radiat Oncol; 2014 Dec; 9():277. PubMed ID: 25497602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intensity-Modulated Radiation Therapy with Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: The Georgetown University Experience.
    Mercado C; Kress MA; Cyr RA; Chen LN; Yung TM; Bullock EG; Lei S; Collins BT; Satinsky AN; Harter KW; Suy S; Dritschilo A; Lynch JH; Collins SP
    Front Oncol; 2016; 6():114. PubMed ID: 27200300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hematuria following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer.
    Gurka MK; Chen LN; Bhagat A; Moures R; Kim JS; Yung T; Lei S; Collins BT; Krishnan P; Suy S; Dritschilo A; Lynch JH; Collins SP
    Radiat Oncol; 2015 Feb; 10():44. PubMed ID: 25890265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.